Canada / Germany Program

If you are looking for a Canadian or European collaborator, please fill out this interest form and return it to Marc Thibault ( as soon as possible.

Candidates had until January 15th, 2016 to submit their short common application form (common call) and full application form.  

To view the complete call for proposals for the 2015 competition, click here.

Scope of the Program

The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany by aligning scientific resources and expertise. This collaborative program gives the opportunity for private and public organizations based in Canada and Germany to develop new expertise and to expand into new markets.

This program is meant to finance the development of novel and potentially transformative next-generation technologies or tools with the potential to improve, enhance or accelerate the state of the art and/or development process. For Canada, the program is focused on biomedical research aimed at developing tools and technologies to improve, accelerate or enhance the drug discovery process. The German funding system is generally technology open.

This program is not intended to fund research on new drugs for specific therapeutic segments.

This program promotes creativity, innovation, multidisciplinarity and collaborative efforts between academic institutions and private organizations (Small and Medium Enterprises or SMEs) from Canada and Germany.

Program Requirements

Each research proposal must:

  • Include a strong collaboration between at least one research entity (public or private) in Canada and at least one private entity in Germany.
    • Please note that in Germany, a private entity (SME) is mandatory to apply. Public and private non-profit research and technology organizations (RTOs) acting as cooperation partners for a SME are also eligible for ZIM-funding.
    • In Canada, the participation of a private organization is highly encouraged and preferred, but not mandatory; universities are eligible.
  • Generate clear deliverables with immediate applications and/or development process. In Canada, focused at improving or enhancing the drug discovery process.
  • Be highly innovative with a strong and wide potential impact in all technological areas. In Canada, focused on impact in biopharmaceutical research.

Research Agenda

The research agenda is broad open to all branches and technological sectors. The program covers all fields and all research areas that could bring new tools that can accelerate the state of the art and in Canada, to enable the drug discovery or development process in various fields of biopharmaceutical research, such as engineering, nanotechnologies, medical devices, diagnostics, translational medicine and imaging. This program is not meant to fund fundamental research projects. Investigators working on applied research projects are strongly encouraged to apply.

Funding Specifics


Minimum 2 years, maximum 3 years

General financing terms :

  • The project contributions from Canada and Germany should be comparable (in terms of resources and/or budget);
  • In Canada, a maximum of $500,000 can be awarded to the Canadian arm of the project, with a minimum of $250,000;
  • The research done in Canada will be directly funded by CQDM as a grant while the research done by the German partners will be funded by ZIM cooperation projects.
  • German specificities;
    • All German SMEs of up to 499 employees are eligible for funding.
    • The research performed in Germany will be funded by the Federal Ministry for Economic Affairs and Energy (BMWi). The financial package will depend on the amount budgeted and, importantly, on the number of partners involved.
    • Both universities and SMEs are eligible for this program (matching funds are required when involving SMEs).
    • The subsidy rates for R&D projects can be found in the table in section 5.2.1 (page 6) of the ZIM guideline. For international projects the subsidy rate will be increased up to 10%-points for companies with at least one foreign partner compared to cooperation projects with domestic partners. However, the maximum is 55%. Hence, matching funds are mandatory for German partners.
  • Canadian specificities;
    • Both SMEs and universities are eligible. The participation of a SME is not mandatory but strongly encouraged.
    • Matching funds for Canadian partners are not mandatory.
    • SMEs of up to 499 employees are eligible for funding.

Eligible costs (for CQDM and Aif):

Eligible costs are defined as reasonable costs for items that directly support the objectives of the project.

  • Salaries of research personnel (students, post-doctoral fellows, technical/professional assistants) and support staff (e.g. project managers) needed for the completion of the project;
  • Material and laboratory supplies required to achieve the project;
  • Subcontracting.

Eligible costs (for CQDM only):

  • Travel expenses (field work, collaborations, conferences);
  • Up to 15% administrative costs or overheads.

Non eligible costs:

  • Equipment or facilities (purchase or rental);
  • Salary of the principal investigator and co-investigators.

Review and Decision Process

Canadian applicants must submit an application using the form available on CQDM’s website ( no later than January 15th, 2016 at 5 p.m. EST via CQDM’s secured website ( The content of this proposal must be developed in collaboration between Canadian and German partners.

All German ZIM applicants need to fill a separate ZIM application form in German language. Submission of the ZIM cooperation projects form has to be done according to ZIM’s guidelines on ZIM’s secured website.

Both partners also have to jointly complete a short common application form (common call) that summarises the project to be submitted to both CQDM and AiF.

Funding will be awarded following a competitive evaluation process:

  • The applications will be evaluated by the respective organizations, AiF’s Scientific and Economic Committees for the German applications and CQDM for the Canadian applications.
  • The scientific excellence, applicability and feasibility of the project will be evaluated jointly by the AiF and CQDM Committees. Evaluators are chosen for their specific scientific and/or industrial expertise in the field of the submitted projects. In parallel, a risk analysis will be conducted by the funding agencies.
  • The applicants may be asked to submit additional information to AiF and CQDM based on recommendations and comments of the evaluation committees.

Scientific evaluation

For German organizations, please refer to the Aif application form.

In Canada, applications will be evaluated based on the following criteria:

  • Potential applicability and impact in drug research and ability to improve, enhance or accelerate the drug development process:
    - immediate impact on drug discovery or development;
    - capacity to address important unmet biopharmaceutical needs;
  • Scientific excellence;
  • Creativity and innovation;
  • Socio-economic impact of the project for the collaborators;
  • Positioning and competitive edge;
  • Feasibility to execute the project within allocated time and budget;
  • Well-defined deliverables, milestones and schedule;
  • Track record of the participants (principal investigator/lead and co-investigators/co-leads);
  • Multi-organizational aspects of the research candidates;
  • Complementarity between partners and quality of the synergy.

Final selection

The final selection of projects will be carried out independently by CQDM’s Strategic Orientation Committee and by AiF’s Scientific and Economic Committees. Approval by both parties is necessary to obtain funding.

Licensing Policy

  • A research agreement must be signed by all research entities involved in the project within 3 months after the funding confirmation;
  • Intellectual property generated under this funding programwill be managed according to the policies of the financial partners involved;
  • A license option will be granted to CQDM’s industrial sponsors (the parent organizations and their subsidiaries) for the use of the results for R&D purposes only. The main conditions of the end-user license option will be negotiated before the beginning of the project and will take into account pre‑existing IP as well as contribution from each party;
  • CQDM’s industrial sponsors will have no rights to commercialize the IP resulting from the project nor the pre-existing IP.